Short interest for Pineapple Express gives investors a sense of the degree to which investors are betting on the decline of Pineapple Express's stock. Short interest data is updated every two weeks.

Pineapple Express (OTC:PNXP) Stock, Short Interest Report

Pineapple Express Cannabis Co along with its subsidiaries, serves as an incubator, helping early-stage ventures and startups in the cannabis sector through funding, mentoring, and training. It is also engaged in legal cannabis retail and owns and manages retail cannabis ventures.

Cannabis

News

Penny Stocks

Entrepreneurship

Retail Sales

Markets

General

AYRWF

PNXP

CSE:AYR

Underground Legacy Operator NJWeedman Goes Legit, Gets Green Light To Open Legal Cannabis Dispensary



Legacy Operator NJWeedman Goes Legit, Meet &amp; Greet With Vic Mensa In IL &amp; More New Cannabis Stores

Image by Benzinga

Offerings

Pineapple Express Cannabis Company (OTCPK: PNXP) has announced a significant move towards expansion and growth.

Pineapple Express Cannabis Company Launches $5M 506(c) Common Stock Offering

PINEAPPLE EXPRES CANNABIS by Pineapple Express Cannabis Company

Pineapple Express Cannabis Co

PLANET VENTURES INC by Planet Ventures Inc

Planet Ventures Inc

A new report by 10x Research explores the recent Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price surge and its potential connection to former President Donald Trump&#8216;s <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39552551/donald-trumps-election-odds-surge-to-64-following-debate-according-to-crypto-bettors">strong position in the 2024 election race.</a>
What Happened: The <a href="https://mail.10xresearch.co/p/bitcoin-trump-pump-sustainable?utm_source=mail.10xresearch.co&amp;utm_medium=newsletter&amp;utm_campaign=is-the-bitcoin-trump-pump-sustainable">report</a>, titled &#8220;Is The Bitcoin Trump Pump Sustainable?&#8221;, highlights a 4% rally in Bitcoin&#8217;s price following news that President Joe Biden will remain in the race despite a <a href="https://www.benzinga.com/news/24/06/39566647/joe-bidens-disastrous-debate-performance-blamed-on-bad-preparation-what-a-bad-decision-to-send-him-o">poor performance</a> in the presidential debate.
This decision, reportedly influenced by <a href="https://www.benzinga.com/news/24/07/39575534/bidens-family-rallies-behind-him-after-disastrous-debate-performance-against-trump">Biden&#8217;s family</a>, comes amid polls suggesting that Biden—or even alternative Democratic candidates like California Governor <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39556388/joe-biden-to-be-replaced-in-2024-election-newsom-tops-democrat-wish-list-betting-odds-but-">Gavin Newsom</a>—would likely lose to Trump in a general election.
Cryptocurrency analyst Markus Thielen notes that Trump, despite being a controversial figure, appears to be the only viable choice for many Americans at present.
The report suggests that Trump&#8217;s popularity and potential return to the White House are viewed positively by cryptocurrency markets, given his crypto-friendly stance.
Seasonally, July tends to be a positive month for Bitcoin, followed by weaker months in August and September. 
This seasonal trend suggests that while Bitcoin could see short-term gains, a <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39580069/why-bitcoin-could-plunge-to-55k-10x-research">drop to $55,000</a> in the coming weeks remains possible.
Traders who bought Bitcoin near $60,000 may see short-term benefits, but medium-term predictions still lean towards lower prices.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/markets/cryptocurrency/24/03/38015356/150-000-bitcoin-boom-expected-in-2024-says-hedge-fund-manager-bitcoin-is-the-king-it-is-th"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39580069/why-bitcoin-could-plunge-to-55k-10x-research">Why Bitcoin Could Plunge To $55K: 10x Research</a>
Why It Matters: Technically, Bitcoin&#8217;s 21-day moving average stands at $63,750, which serves as a crucial level for reconsidering the bearish outlook.
The trend model has a moving stop at $68,900, with the $61,500 to $61,800 range being particularly significant for maintaining price levels.
<a href="https://www.benzinga.com/money/how-to-mine-bitcoin">Bitcoin mining</a> companies face additional challenges during the summer months, particularly in Texas, where many operations are based.
High temperatures can lead to grid outages, potentially causing further selling pressure from miners needing to fund their operations as prices approach the $60,000 breakeven mark.
In recent weeks, Bitcoin balances on exchanges have increased by +18,500 BTC, though the 30-day flow remains negative at -12,500 BTC.
This increase in exchange balances typically signals a readiness to sell, explaining the recent +4% weekend rally. It appears that some traders might have pushed prices up to sell more Bitcoin at higher levels.
Money flow indicators do not suggest sustainable liquidity entering the crypto market. 
Notably, Circle&#8216;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) has seen significant outflows, indicating a move from crypto back into fiat. Furthermore, discrepancies in <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39592240/what-is-going-on-with-bitcoin-spot-etfs">ETF flow</a> data from Farside and Blackrock have raised questions about the reliability of these metrics.
Despite Trump's lead in the polls being viewed positively for Bitcoin, the report concludes that consolidation is likely ahead. 
Potential <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39577189/will-mt-gox-really-dump-9b-in-bitcoin-on-the-market">Mt. Gox Bitcoin flows this month</a>, combined with sales from entities like the German government, could impact the market. Increased exchange balances and a potential decline in stablecoin growth are critical indicators to watch.
What&#8217;s Next: These dynamics and their implications for the cryptocurrency market will be a central topic at Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39581378/doj-division-chooses-coinbase-as-partner-to-custody-32m-in-assets">DOJ Division Chooses Coinbase As Partner To Custody $32M In Assets</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$USDC

Is The 'Bitcoin Trump Pump' Sustainable? Here's What 10x Research Thinks

<a href="https://www.bloomberg.com/news/articles/2024-07-02/tyson-pulls-back-on-beef-without-antibiotics-after-similar-move-with-chicken?sref=y3YMCJ4e" title="https://www.bloomberg.com/news/articles/2024-07-02/tyson-pulls-back-on-beef-without-antibiotics-after-similar-move-with-chicken?sref=y3YMCJ4e">https://www.bloomberg.com/news/articles/2024-07-02/tyson-pulls-back-on-beef-without-antibiotics-after-similar-move-with-chicken?sref=y3YMCJ4e</a>

Bloomberg Reported Earlier, Tyson Foods  Is Downsizing Its Antibiotic-free Beef Offerings

Keybanc analyst Todd Thomas maintains Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) with a Overweight and raises the price target from $95 to $115.

Price Target

Analyst Ratings

WELL

Keybanc Maintains Overweight on Welltower, Raises Price Target to $115

Keefe, Bruyette &amp; Woods analyst Bose George maintains Stewart Information Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STC#NYSE">STC</a>) with a Market Perform and lowers the price target from $64 to $61.

Keefe, Bruyette & Woods Maintains Market Perform on Stewart Information Servs, Lowers Price Target to $61

Keybanc analyst Upal Rana maintains Kilroy Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRC#NYSE">KRC</a>) with a Overweight and lowers the price target from $45 to $42.

Keybanc Maintains Overweight on Kilroy Realty, Lowers Price Target to $42

Keefe, Bruyette &amp; Woods analyst Bose George maintains Fidelity National Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) with a Market Perform and lowers the price target from $55 to $53.

Keefe, Bruyette & Woods Maintains Market Perform on Fidelity National Finl, Lowers Price Target to $53

Keefe, Bruyette &amp; Woods analyst Bose George maintains First American Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FAF#NYSE">FAF</a>) with a Outperform and lowers the price target from $67 to $63.

Keefe, Bruyette & Woods Maintains Outperform on First American Financial, Lowers Price Target to $63

Last week,&nbsp;<a href="https://www.benzinga.com/news/24/07/39569675/palantirs-peter-thiel-says-its-very-strange-that-most-money-in-ai-is-being-made-by-only-one-company">at the Aspen Ideas Festival</a>,&nbsp;Palantir Technologies&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) co-founder Peter Thiel underscored the pivotal role founders play in the success of their companies while giving the example of Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) CEO Mark Zuckerberg.
What Happened: Thiel&#8217;s remarks were part of a broader conversation about his book &#8220;Zero to One.&#8221; When asked about his perspective on the role of founders, especially those with unconventional or extreme personalities, Thiel asserted that many prosperous companies were founded by individuals who viewed their business as a life project.
He further explained that these founders often possess unique visions and are capable of creating something extraordinary over time. Despite their extreme personalities and potential blind spots, Thiel argued that their contribution is &#8220;massively advantageous&#8221; compared to hiring a professional CEO.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/06/39562427/metas-ray-ban-smart-glasses-face-new-rival-powered-by-openais-chatgpt?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Meta&#8217;s Ray-Ban Smart Glasses Face New Rival Powered By OpenAI&#8217;s ChatGPT</a>
Thiel used the example of&nbsp;Facebook, <a href="https://www.benzinga.com/general/social-media/23/04/32098803/if-you-invested-1-000-in-facebook-stock-when-it-changed-name-to-meta-platforms-heres-how-muc">now rebranded as Meta</a>,&nbsp;founder Zuckerberg, who rejected a $1 billion acquisition offer from&nbsp;Yahoo in 2006. He pointed out that a professional CEO would have likely accepted the offer, highlighting the unique perspective and dedication founders bring to their companies.
&#8220;If you had a professional CEO, it would have just been &#8216;man I can't believe they're offering us a billion dollars. I'm going to try not to be too eager. We better take the money and run,'&#8221; he said referring to Zuckerberg.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f52e; &#x1f6a8;NEW Peter Thiel interview! Here are ALL of the best clips&#x1f447;&#x1f9f5;<a href="https://twitter.com/search?q=%24PLTR&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$PLTR</a> co-founder Peter Thiel on the importance of Founders and the story of Zuckerberg turning down the $1B Facebook &#8211; Yahoo buyout offer: "If you had a professional CEO, it would have just been ‘man I can't… <a href="https://t.co/AQWFILINmT">pic.twitter.com/AQWFILINmT</a>
&mdash; Jawwwn (@jawwwn_) <a href="https://twitter.com/jawwwn_/status/1806705261551202550?ref_src=twsrc%5Etfw">June 28, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Thiel was an early backer of Facebook. He invested $500,000 in the company in 2004, which gave him a significant stake. He also served on Facebook&#8217;s board of directors for many years, <a href="https://www.benzinga.com/markets/cryptocurrency/22/03/26300941/billionaire-investors-marc-andreessen-peter-thiel-could-leave-meta-board-over-crypto-invol">stepping down from the board in 2022</a>. 
His latest comments resonate with the historical context of Zuckerberg&#8217;s decision to decline Yahoo&#8217;s $1 billion offer. According to a 2017 Business Insider <a href="https://www.businessinsider.in/tech/inside-mark-zuckerbergs-controversial-decision-to-turn-down-yahoos-1-billion-early-offer-to-buy-facebook/articleshow/58210727.cms">report</a>, Zuckerberg&#8217;s refusal was controversial at the time.
However, his decision has since been vindicated, with Meta boasting a market cap of $1.280 trillion, making it the seventh most valuable company in the world.
Previously, Zuckerberg also discussed his thought process when these deals were offered. In conversation with Dwarkesh Patel, the Meta CEO was asked, &#8220;Did you write down in your head like ‘I think the actual valuation of Facebook at the time is this and they're not actually getting the valuation right?' If they&#8217;d offered you $5 trillion, of course, you would have sold. So how did you think about that choice?&#8221;
Zuckerberg admitted that he wasn't &#8220;sophisticated enough to do that analysis&#8221; at the time. However, he had people presenting arguments both for and against the deals. &#8220;It was very far ahead of where we were at the time. I didn't really have the financial sophistication to really engage with that kind of debate,&#8221; he said.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:&nbsp;<a href="https://www.benzinga.com/news/24/07/39568912/apple-iphone-settlement-deadline-extended-users-get-extra-time-to-file-claims-to-get-up-to-349?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple iPhone Settlement Deadline Extended: Users Get Extra Time To File Claims To Get Up To $349</a>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Tech

PLTR

Palantir's Peter Thiel Highlights Impact Of Founders, Citing Mark Zuckerberg's Example Of Not Selling Facebook To Yahoo For $1B: 'If You Had A Professional CEO…'

WIIM

GILT

Gilat Satellite Networks shares are trading higher after the company's US-based subsidiary, DataPath, announced over $9 million in orders in support of the DoD and other agencies.

WideOpenWest shares are trading lower after Raymond James downgraded the stock from Market Perform to Underperform.

HUMA

Humacyte shares are continuing higher after the company on Monday announced it was granted Regenerative Medicine Advanced Therapy designation by the FDA for patients with advanced peripheral artery disease.

TRAK

ReposiTrak Adds 25 New Produce Suppliers To Its Food Traceability Network

Checkpoint Therapeutics, Inc. (&quot;Checkpoint&quot;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CKPT#NASDAQ">CKPT</a>), a clinical-stage immunotherapy and targeted oncology company, today announced it has completed the resubmission of its Biologics License Application (&quot;BLA&quot;) to the U.S. Food and Drug Administration (&quot;FDA&quot;) for cosibelimab, its anti-programmed death ligand-1 (&quot;PD-L1&quot;) antibody, as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (&quot;cSCC&quot;) who are not candidates for curative surgery or curative radiation. 
&nbsp;
The BLA resubmission follows Checkpoint recently reaching alignment with the FDA on its BLA resubmission strategy to potentially address all approvability deficiencies outlined in the complete response letter (&quot;CRL&quot;) received last December, in which FDA only cited findings that arose during a multi-sponsor inspection of Checkpoint&#39;s third-party contract manufacturing organization (&quot;CMO&quot;) as approvability issues to address in a BLA resubmission. The CRL did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab.
The BLA resubmission is supported by the results of Checkpoint&#39;s studies in selected recurrent or metastatic cancers, including pivotal cohorts in metastatic and locally advanced cSCC. Safety and efficacy results from the metastatic cSCC cohort were published in October 2023 in the&nbsp;Journal for ImmunoTherapy of Cancer (JITC)&nbsp;(doi:10.1136/jitc-2023-007637).
Additionally, in July 2023, Checkpoint announced longer-term data for cosibelimab from its pivotal studies in locally advanced and metastatic cSCC demonstrating a deepening of response over time, resulting in higher complete response rates than previously reported (55%&nbsp;objective response rate;&nbsp;26%&nbsp;complete response rate in locally advanced cSCC and&nbsp;50%&nbsp;objective response rate;&nbsp;13%&nbsp;complete response rate in metastatic cSCC).
Cosibelimab is a potential differentiated, high affinity, fully-human monoclonal antibody of IgG1 subtype that directly binds to PD-L1 and blocks the PD-L1 interaction with the programmed death receptor-1 (&quot;PD-1&quot;) and B7.1 receptors. Cosibelimab&#39;s primary mechanism of action is based on the inhibition of the interaction between PD-L1 and its receptors PD-1 and B7.1, which removes the suppressive effects of PD-L1 on anti-tumor CD8+ T-cells to restore the cytotoxic T-cell response. Cosibelimab is potentially differentiated from the currently marketed PD-1 and PD-L1 antibodies through sustained high tumor target occupancy of PD-L1 to reactivate an antitumor immune response and the additional potential benefit of a functional Fc domain capable of inducing antibody-dependent cell-mediated cytotoxicity (&quot;ADCC&quot;) for potential enhanced efficacy.

Government

Regulations

CKPT

Checkpoint Therapeutics Resubmits BLA for Cosibelimab to FDA for Advanced Skin Cancer Treatment

INCY

Incyte shares are trading lower after BMO Capital downgraded the stock from Market Perform to Underperform and lowered its price target from $52 to $48.

Proceeds from the facility are intended to provide non-dilutive working capital to support the Company&#39;s ongoing global CytoSorb&reg; franchise in critical care and cardiac surgery that generated $32.2 million in trailing 12-month sales as of March 31, 2024, planned marketing applications to U.S. Food and Drug Administration (FDA) and Health Canada for DrugSorb&trade;-ATR and initial launch and commercialization preparations if approved, and refinancing of existing Bridge Bank debt.

Biotech

Health Care

Financing

CTSO

CytoSorbents Entered Into A New $20M Credit Facility With Avenue Capital Group

KRMD

KORU Medical Systems Receives Regulatory Clearance For FreedomEdge Infusion System In Japan

Chinese electric vehicle manufacturer BYD Company (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) reported a 21% increase in <a target="_blank" href="https://www.benzinga.com/electric-vehicles" rel="noreferrer noopener">electric vehicle sales</a> for the second quarter.
BYD sold 426,039 EVs from April to June, approximately 12,000 units fewer than Tesla, Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) estimated deliveries, reported Reuters.
Tesla is anticipated to announce a 6% decline in second-quarter deliveries, marking the first consecutive quarterly drop as it grapples with fierce competition in China and tepid demand for its older models, the report noted.
BYD had earlier reported a jump in passenger vehicle sales for the month of <a target="_blank" href="https://www.bydglobal.com/sitesresources/common/tools/generic/web/viewer.html?file=%2Fsites%2FSatellite%2FBYD%20PDF%20Viewer%3Fblobcol%3Durldata%26blobheader%3Dapplication%252Fpdf%26blobkey%3Did%26blobtable%3DMungoBlobs%26blobwhere%3D1638928473079%26ssbinary%3Dtrue" rel="noreferrer noopener">June </a>2024, with a total of 340,211 vehicle deliveries.
Battery electric vehicle sales increased to 145,179 vehicles and that of New energy vehicles (NEV) rose to 341,658 units.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39588835/tesla-q2-deliveries-fund-manager-predicts-4-shortfall-ross-gerber-calls-it-a-low-bu" rel="noreferrer noopener">Tesla Q2 Deliveries: Fund Manager Predicts 4% Shortfall, Ross Gerber Calls It A &#8216;Low But Special Number&#8217;</a>
While Tesla has cut production of its Model Y at its Shanghai plant due to waning demand, BYD has maintained robust growth, the report mentioned.
EV startups like Nio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) also saw impressive gains, with <a target="_blank" href="https://www.benzinga.com/news/24/07/39574028/whats-going-on-with-chinese-ev-stocks-nio-li-auto-xpeng-on-monday" rel="noreferrer noopener">NIO&#8217;s Q2 deliveries</a> more than doubling to over 57,300 units.
Price reductions and a shift towards electric and hybrid vehicles have bolstered sales for Chinese EV manufacturers.
In May, new energy vehicles comprised 46.7% of total car sales in China, setting a new monthly record, according to the China Passenger Car Association (CPCA).
Price Action: BYDDY shares closed higher by 1.12% at $59.74 on Monday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/06/39477448/byd-launches-third-ev-model-in-toyota-homeground-priced-aggressively-to-compete-against-popular-rav4" target="_blank" rel="noreferrer noopener">BYD Launches Third EV Model In Toyota Homeground, Priced Aggressively To Compete Against Popular RAV4 PHEV</a></li>
</ul>

Equities

Media

BYDDY

TSLA

Tesla Rival BYD's EV Sales Jump 21% In Q2: Details

Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) (TASE: EVGN), is pleased to announce the commercial expansion of its bio-inoculant product, Yalos&trade;, to winter wheat, following successful trials. This expansion effectively doubles the potential market for Yalos&trade; compared to markets in which&nbsp;Lavie Bio&nbsp;already operates. Winter wheat growers across the US will have access to Yalos&trade; for the upcoming 2024-2025 season.
<img alt="Evogene" src="https://mma.prnewswire.com/media/1947468/Evogene.jpg" />
Winter wheat is one of the crucial crops in&nbsp;North America&nbsp;and globally, significantly contributing to the agricultural economy and food supply. The US is expected to produce about 1.28 billion bushels in 2024[1], with a market value, according to&nbsp;Lavie Bio&#39;s&nbsp;estimation, between&nbsp;$5-$10 billion&nbsp;annually. Introducing Yalos&trade; to this market offers substantial potential to capture market share by enhancing crop productivity and sustainability. To date,&nbsp;Lavie Bio&nbsp;has focused on the spring wheat market, along with durum and barley, which together form a smaller market compared to winter wheat.
During the successful field trials, Yalos&trade; has demonstrated enhanced early vigor, biomass, root and shoot development, nutrient availability, and feed quality in winter wheat. Yalos&trade; aims to reduce crop abandonment rates and increase farm productivity through advanced biological technologies.
In addition,&nbsp;Lavie Bio&nbsp;is expecting to expand Yalos&trade; into other key crops, such as soybean and canola, with ongoing field trials in&nbsp;North America&nbsp;and an expected commercial launch in 2025. The US soybean market size is estimated by&nbsp;Lavie Bio&nbsp;at approximately&nbsp;$56.2&nbsp;billion in 2024.

EVGN

Lavie Bio Expands Yalos Bio-Inoculant to Winter Wheat Market, Doubling Potential Reach

SYTA

Siyata Mobile Makes Strategic Investment in Canadian Towers & Fiber Optics

Garmin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>), the world&#39;s most innovative and recognized marine electronics manufacturer, today announced it was selected as the exclusive marine electronics and audio supplier for Independent Boat Builders, Inc. (IBBI), the industry&#39;s largest purchasing cooperative. Beginning model year 2025, this agreement gives IBBI member-owners direct access to Garmin&#39;s full line of marine electronics and audio solutions, including JL Audio&reg;, Fusion&reg;&nbsp;and Clarion Marine, through 2029. Comprised of a 15-owner network of leading boat brands, IBBI members collectively build more than&nbsp;25%&nbsp;of all boats sold in the U.S.
<a href="https://mma.prnewswire.com/media/2451039/Garmin_selected_by_IBBI.html" target="_blank"><img alt="Garmin was selected as the exclusive marine electronics and audio supplier for Independent Boat Builders, Inc. (IBBI), the industry's largest purchasing cooperative, through 2029." src="https://mma.prnewswire.com/media/2451039/Garmin_selected_by_IBBI.jpg" /></a>
&quot;We are so pleased to extend and strengthen our long-standing relationship with these boat builders to include both electronics and audio exclusively from Garmin. From chartplotters and navigation with leading Garmin Navionics+&trade;&nbsp;mapping to trolling motors, stereos, speakers and more, Garmin offers a robust product portfolio known for quality and innovation&mdash;backed by award-winning support&mdash;that will continue to benefit our mutual customers now and into the future.&quot;
&ndash;Dan Bartel,&nbsp;Garmin&nbsp;Vice President of Global Consumer Sales
IBBI member-owners have chosen Garmin for over a decade. Prior to becoming its exclusive marine electronics supplier in 2018, Garmin had been a supplier of choice for IBBI since 2014. In 2019, audio was added when Fusion was named IBBI&#39;s marine stereo and entertainment supplier of choice. Garmin was also the recipient of IBBI&#39;s prestigious Supplier of the Year award in 2018, 2019 and 2024, a direct result of its dedication to IBBI boat builders and the group&#39;s collective customers.&nbsp;&nbsp;&nbsp;
&quot;Garmin continues to set the standard when it comes to product innovation and customer service, and we are proud to continue doing business with such a trusted and recognized manufacturer. From product quality to support, the members of IBBI continue to be impressed with Garmin and the great benefits they provide to the end customer so extending our agreement was an easy decision.&quot;
&ndash;Tom&nbsp;Broy, IBBI President&nbsp;

								Get Alert
PNXP	Pineapple Express Cannabis Com	04/24/2024	—	—	91	186	1	Get Alert
PNXP	Pineapple Express Cannabis Com	04/09/2024	—	—	85	20	4.25	Get Alert
PNXP	Pineapple Express Cannabis Com	03/26/2024	—	—	41	27	1.52	Get Alert